Preventive health: which startup is ahead?

Which preventive-health startups belong in this race?

Preventive health currently has eight startups worth comparing closely: Neko Health, Function Health, Prenuvo, Everlab, Superpower, Fountain Life, Biograph and Q Bio.

We include companies that build a broad health baseline from several types of data and then help customers interpret or track it. The mix can include blood biomarkers, imaging, skin checks, cardiovascular measurements, genetics, wearables and medical records. We exclude wearables such as Oura and Whoop, single-purpose tests such as GRAIL’s cancer assay, and older providers such as Human Longevity. Ezra drops out as a separate competitor because Function Health acquired it.

The category needs a clear boundary. Neko runs an integrated physical checkup. Function and Superpower begin with laboratory memberships. Prenuvo specializes in whole-body MRI. Everlab coordinates diagnostics and follow-up through a provider network. Fountain Life and Biograph sell expensive, physician-heavy programs. Q Bio is rebuilding the physical exam around MRI, biomarkers, genetics and longitudinal records. These companies compete for the same customers, but their products work very differently.

Funding figures below are approximate because private-market databases treat debt, older seed rounds and currency conversion differently. Function’s latest money also comes from a growth-financing fund tied to customer growth rather than a classic equity round, so its total is not directly comparable with pure venture rounds.

Startup	What it sells	Approximate cumulative funding
Neko Health	One-hour clinic check covering skin, heart, blood and metabolic health, followed by a clinician consultation	About $1.03B from a €60M Series A, a $260M Series B and a $700M Series C (July 2026, valuation near $7B)
Function Health	Membership with 160+ lab tests, clinician-reviewed insights, health tracking and optional imaging	More than $800M, including $450M of growth financing from General Catalyst’s Customer Value Fund (July 2026)
Prenuvo	Whole-body MRI screening, biomarker testing and recurring preventive-health memberships	About $275M, including debt in the database total
Q Bio	A physical exam combining whole-body MRI, biomarkers, genetics, wearables and physician review	About $80M
Everlab	A preventive-care platform linking diagnostics, doctors, specialists, prescriptions and ongoing follow-up	About $56M across its seed and AU$65M Series A (June 2026)
Biograph	Premium preventive assessments with imaging, cardiovascular testing and long-term clinical support	About $53.9M according to PitchBook data reported by SFGATE
Fountain Life	High-end longevity memberships combining imaging, biomarkers, physicians and selected treatments	About $52M, although published database totals vary
Superpower	Low-cost laboratory membership with 100+ biomarkers, a digital plan and continuous care-team access	About $51M

Can Neko Health hold its lead now that it has opened in New York?

Yes, for now. Neko Health is still ahead overall, but Function Health is close enough to make this a two-company race.

Neko has the best mix of demand, repeat use and product ownership. It controls its hardware, software and clinical workflow. More than 100,000 people have been scanned in Sweden and the UK, and more than 350,000 have registered or joined a waitlist. In July 2026 it raised $700 million at a valuation near $7 billion, and on 24 September it opened a seven-room clinic in SoHo, New York, priced at $499.

The US start was slower than planned. In March 2026, Neko said its first US site would open in the spring; it opened in late September. Demand did not suffer: Athletech News reported that the US waitlist grew from about 25,000 to more than 50,000 people in roughly two weeks. Neko has not yet shared US rebooking figures, which is the number that matters.

Function is stronger on reach and price. It charges $365 a year, works through more than 2,000 US lab locations and has bought Ezra for imaging, Getlabs for home blood draws and SuppCo for supplement tracking. Reported membership above 500,000 makes it several times larger than Neko by customers served.

Prenuvo stays third because its lead sits in one part of the category. It runs the biggest dedicated whole-body MRI operation, yet its product is more expensive and narrower than a full preventive-care relationship.

Our call: Neko still has the best complete product, and Function has the easiest path to mass distribution. We keep Neko first because proven repeat payment and control of the full experience matter more than raw reach in a service that still has to earn trust. New York will show whether that holds outside Europe.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Which preventive-health startup has the strongest real-world demand and growth?

Function Health has the largest preventive-health customer base; Neko Health shows the strongest paid demand per person served.

Function has served more than 500,000 members since 2023 and members have logged more than 100 million lab tests, according to Athletech News; MedCity News also reported the 100 million test figure. Function’s own website still says 75 million results delivered, so the public counts do not match yet. Either way, Function operates at a consumer scale nobody else in this group discloses. The 500,000 figure is cumulative, so it does not tell us how many members are active today.

Neko has scanned more than 100,000 people in Sweden and the UK. The 350,000 people who registered or joined a waitlist equal about 3.5 times the number already scanned. In the US, the waitlist passed 50,000 in roughly two weeks. Demand is still running ahead of capacity.

Prenuvo’s imaging biobank now holds more than 200,000 whole-body MRI scans, the company said in September 2026. That puts its delivered imaging volume above Neko’s scan count, although the two services cover different medical needs.

Superpower now gives a number: its website says it has more than 64,000 members. That is company-stated and not defined as active or paid annual members, but it moves Superpower clearly above the smaller players.

Everlab reports 20,000 patients, more than 40,000 consultations, 21 million biomarker results and over 200,000 health reports processed each month. The monthly report figure is ten times its patient count, which supports Everlab’s claim that repeated care drives the product.

The gap below these five is large. Biograph says it has served thousands of clients, Fountain Life has a small premium-center network, and Q Bio still delivers directly through one flagship clinic and selected partners. None has published new usage data in 2026 that would change its position.

Do customers come back for another preventive-health check?

Neko Health has the best public retention evidence in preventive health, and nobody else shows a comparable renewal number.

At the end of a first Neko appointment, 75% of members book and prepay for next year’s scan. Neko now adds that 80% book a third scan after their second. Prepayment makes this much stronger than a waitlist or an automatic subscription. The customer has spent an hour in the clinic, seen the results and still chooses to pay again.

Neko has also studied 1,469 customers who completed a second annual assessment and reported improvements in blood pressure, cholesterol and blood sugar. The analysis is company-produced and returning customers may be more motivated than average, but it shows repeat use already exists at scale.

Function, Superpower and Prenuvo all sell recurring relationships, yet none publishes a comparable renewal rate. Function’s new financing comes from a fund that backs customer growth, which suggests its investors have seen solid customer economics. That is an inference, not a disclosed retention figure.

This is still Neko’s clearest edge over Function. Function reaches far more people, but only Neko has shown that customers who finish the full experience pay to repeat it, twice.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Which preventive-health product is ready to scale now?

Function Health has the easiest preventive-health model to scale; Neko Health still offers the most complete clinic product.

Function can use more than 2,000 lab locations, offer home collection through Getlabs and sell MRI or CT scans at more than 200 imaging locations through the Ezra network. Most of the expensive infrastructure already exists. Function mainly has to coordinate access, standardize the experience and make the data useful. Distribution deals help too: Athletech News reported that Robinhood now offers Function as a perk on its Platinum Card.

Neko faces a heavier rollout. Each opening needs its own devices, suitable real estate, trained staff and local approvals. Neko plans a second Manhattan clinic at Brookfield Place in January 2027 and a Miami site by the end of 2026, with San Francisco and Washington, D.C. in the pipeline. These are plans, not open clinics. The slip of its first US opening from spring to September shows how hard each new market is.

Prenuvo has already shown that a complex imaging service can run across North America and London. Its challenge is keeping protocols, image quality and radiologist reading consistent across a growing network. The company stresses structured reporting and dedicated whole-body readers. Those are company claims, but they target the right bottlenecks.

Everlab offers a fourth route. Its platform connects to more than 1,850 provider locations, 180 active clinicians and over 30 wearable devices. Everlab said in June 2026 that its global rollout starts with the UK, but it has not given a launch date.

Q Bio remains much earlier. Its 75-minute exam is bookable in Redwood City and through enterprise partners, but the company has disclosed no patient volume.

Startup	Product maturity	How it scales	Main constraint
Function Health	Fully commercial across the US	Existing labs, 200+ imaging locations, home collection and distribution partners	Turning several partners into one coherent care experience
Neko Health	Fully commercial in the UK and Sweden; first US clinic open in New York since September 2026	Repeatable owned clinics using proprietary devices	Clinic construction, approvals and medical staffing
Prenuvo	Fully commercial across North America and London	Dedicated and partner MRI locations	Price, radiology capacity and protocol consistency
Everlab	Commercial across Australia and New Zealand; UK launch announced, no date	Large provider and clinician network	Maintaining consistent care across markets
Superpower	Nationally available laboratory membership, 64,000+ members (company-stated)	Partner labs and digital care	No public data on renewal or active members
Fountain Life	Mature premium service	Owned centers and high-touch teams	Very high price and staff intensity
Biograph	Mature premium assessment in two cities	Owned clinics and specialist follow-up	Small footprint and expensive memberships
Q Bio	Commercial but early	Flagship clinic plus enterprise partners	One disclosed clinic and opaque patient volume

Which preventive-health startup gives customers the best value?

Function Health offers the strongest value in preventive health today.

Function charges $365 a year for more than 160 lab tests, split across two visits, with clinician-reviewed findings and a personal plan. Athletech News notes the price came down from $499 in November 2025. That works out to about $2.28 per listed test before counting the software and medical review. The math oversimplifies lab economics, but it shows how far Function has pushed broad testing below executive-health prices.

Superpower costs $199 a year for more than 100 biomarkers from one blood draw, plus a care team. Its price per listed marker falls below $2. It is the cheapest credible broad lab product in the field, though one annual draw gives less tracking than Function’s two.

Neko charges £299 in the UK and $499 in New York for a one-hour assessment, same-day results and a clinician consultation. Function and Superpower give more lab breadth, but neither recreates Neko’s skin imaging, heart measurements, on-site 53-biomarker blood panel and in-person explanation in one visit. For a physical clinic product, both prices are aggressive.

Function also pulled down the price of imaging after buying Ezra. It now sells MRI and CT add-ons for under $1,000 at more than 200 locations. Sources differ on the entry price of its full-body MRI: launch coverage in 2025 cited $499, while MobiHealthNews puts it at $899. Prenuvo argues that cheap and expensive scans can differ sharply in protocol and reading, so price alone settles little.

The premium clinics serve another customer. Biograph charges about $7,500 to $15,000 a year, while Fountain Life lists its APEX membership at $21,500. Those programs include more physician time, but their prices keep them outside the mass-market race.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Which preventive-health startup has the strongest medical evidence?

Prenuvo has the strongest formal research program, but no startup has proved that broad screening improves long-term outcomes for the average healthy customer.

In September 2026, Prenuvo launched the Prenuvo Research Network, built on an imaging biobank of more than 200,000 whole-body MRI scans and partners from more than 50 institutions, including City of Hope, UCSF and Moffitt Cancer Center. One launch study looked at incidental brain findings in more than 78,000 people and reported clinically significant abnormalities in 7%. Another reviewed kidney lesions across 117,826 scans and found most were small and likely benign.

Its best-known cancer study followed about 1,000 self-paying people: radiologists flagged 41 potentially cancerous findings, and follow-up reportedly confirmed cancer in roughly half, a detection rate near 2.2%. These are detection numbers. They show what the scans find, not whether finding it helps people live longer.

That is the hard question. Finding more abnormalities helps only when earlier detection improves treatment enough to outweigh biopsies, repeat scans, anxiety and overdiagnosis. Prenuvo’s Hercules study plans to follow 10,000 people over ten years and could give a stronger answer.

Neko’s evidence focuses on what happens after a broad physical check. In 4,362 Stockholm scans, it reported that 1.2% revealed a previously unknown life-threatening condition needing urgent care. Its returning-member analysis found improvement in five of seven key biomarkers. Both datasets are useful, but Neko produced them itself and neither has a randomized control group. Neko is also clear about limits: its scan is not an MRI and does not screen for most cancers.

Independent medicine remains cautious. The American College of Radiology says the evidence is insufficient to justify total-body MRI screening for people without symptoms or risk factors. A recent systematic review reached the same broad view: whole-body MRI finds cancers in healthy groups, while standards, follow-up and proof of better outcomes remain incomplete.

Prenuvo leads on evidence, Neko has the best repeat-use data, and the survival study that could change medical practice is still missing.

Who actually helps when a preventive-health test finds something?

Neko Health gives the clearest same-day medical handoff at a mass-market price.

Every Neko assessment ends with a clinician explaining the findings during the visit. Customers leave with context instead of a dashboard full of unexplained red flags. In New York, Neko has also set up referral partners: Columbia University Irving Medical Center, Mount Sinai Health System and Schweiger Dermatology. That gives a US member a defined next step when the scan finds something.

Everlab coordinates diagnostics, physicians, specialists, prescriptions and ongoing care through one platform. It works with more than 180 active clinicians and names Boston Consulting Group, BHP and Bain & Company among its corporate customers, the strongest disclosed employer validation in the group.

Function says clinicians review every result and flag issues, then the platform builds a plan. It gives interpretation and easy access to testing, while diagnosis and treatment still depend on outside providers. Its next challenge is making lab tests, imaging, home visits and outside care feel like one relationship.

Prenuvo includes a provider review and works with care companies such as Baker Health and Parsley Health. That improves the path from imaging to follow-up, although many findings still need referral into another medical system.

Biograph and Fountain Life provide the deepest hands-on care. Biograph uses multidisciplinary testing and connects members with specialists. Fountain Life combines imaging, biomarkers, physicians and continuous access. Their clinical depth is real, but price and a small center count keep them at the luxury end.

Which preventive-health product is hardest to copy?

Neko Health owns the hardest complete preventive-health product to reproduce.

Neko designs its own devices, software and clinical protocols, then delivers them through clinics it controls. A competitor would need medical hardware, automated measurement, clinic workflow, regulatory approval, clinician training and an experience that makes people return every year. Buying lab capacity from a partner solves only a small piece.

Prenuvo’s advantage comes from depth in one modality. A biobank of more than 200,000 whole-body scans, built with standardized protocols, is now the base of a formal research network. A new imaging brand cannot reproduce that archive quickly.

Function’s physical inputs are easier to access because labs, imaging centers and mobile phlebotomy already exist. Its defense is moving to another layer: a large longitudinal dataset from more than 100 million tests, a known consumer brand and the ability to join blood results, imaging, supplements and records in one app. Buying Ezra, Getlabs and SuppCo speeds that up and removes possible rivals.

Q Bio may have the most ambitious technical design after Neko. Its exam combines whole-body MRI, biomarkers, genetics, wearables and physician review, and its FDA-cleared Constellation software supports MRI analysis. Commercial proof is still limited to a flagship clinic and partners.

The product-performance question stays partly open because these services measure different things. Neko offers far less anatomical detail than a dedicated MRI, while Prenuvo leaves out blood testing and skin checks. No independent head-to-head study shows one service finding more useful disease with fewer false alarms. We can rank defensibility with more confidence than diagnostic superiority.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Who gets the most reach per dollar: Function, Prenuvo or Superpower?

Superpower and Prenuvo now show the most reach per dollar raised, with Function close behind and Neko far behind.

Superpower has raised about $51 million and says it has more than 64,000 members, or roughly $800 of funding per member. The member figure is company-stated and undefined, so the ratio is only a rough guide.

Prenuvo’s estimated $275 million divided by more than 200,000 scans in its biobank equals about $1,375 per scan. Function has raised more than $800 million and reports more than 500,000 members since launch, or about $1,600 per member. Function’s ratio would look better without the $450 million July 2026 financing, which is meant to fund future customer growth rather than past delivery; without it, Function would top this measure. Everlab’s roughly $56 million across 20,000 patients comes to about $2,800 per patient.

Neko’s roughly $1.03 billion divided by 100,000 people scanned gives about $10,300 per historical scan. The ratio is heavy because the $700 million round funds future US and UK clinics, while older capital paid for years of device and regulatory work. Even so, Neko carries the highest burden of proof in the sector.

These ratios measure capital intensity, not acquisition cost, revenue or profit. Biograph and Fountain Life disclose too little to compare, and Q Bio has raised about $80 million while running one disclosed flagship clinic.

Our judgment: the efficiency story has shifted toward the lab-membership players. Superpower looks lean but unproven on retention, Function has scale and fresh fuel, and Neko still has to turn its large war chest into clinics that fill as fast in America as in Europe.

Is Function Health catching Neko Health after its $450M raise?

Function Health is closing the gap, but Neko Health still has the broader momentum.

Neko raised $700 million in July 2026, opened its seven-room SoHo clinic in September with US demand still ahead of capacity. It also appointed Dr. Sunita Mishra, formerly chief medical officer at Amazon Health, as its own CMO in March 2026. Funding, geography and medical leadership are moving together.

Function’s momentum comes from building a larger platform. In 2026 it bought Getlabs in April and SuppCo in May, then closed $450 million from General Catalyst’s Customer Value Fund in July. Coverage describes that money as financing tied to customer growth rather than a traditional equity round, and no new valuation was disclosed; the last one was $2.5 billion in November 2025. The money is aimed at acquiring members, which is exactly where Function already leads.

Everlab raised AU$65 million in June 2026 at a valuation The Australian reported as approaching AU$500 million, and it has picked the UK as its first market outside Australia and New Zealand. Until it opens there, its momentum stays mostly regional.

Prenuvo is moving from selling a scan toward selling an annual relationship and a research platform. The September 2026 research network strengthens its evidence story, while London gives it a European base. It is moving in the right direction, but Neko and Function are changing faster across more of their business.

Four things could change the ranking. Function could take first place by disclosing strong retention. Neko could lose ground if US clinics fill slowly or rebook less than in Europe. Prenuvo could climb if its long-term research shows better outcomes. Superpower could join the top three if its member base keeps growing at $199 a year.

Which preventive-health startups are actually ahead?

Neko Health is still the preventive-health startup ahead overall, followed closely by Function Health and then by Prenuvo.

We put Neko first because it combines a differentiated product, substantial paid use, the strongest disclosed repeat demand, same-day clinical interpretation and the hardest system to copy. Function is the closest challenger: it reaches several times more people, costs less, has fresh capital for growth and can expand through existing infrastructure. The gap is small and could reverse if Function proves retention or if Neko’s New York clinics fail to match its European results.

Prenuvo holds third place through clear leadership in whole-body MRI and the deepest research effort. Superpower moves to fourth because it now discloses more than 64,000 members at the lowest price in the field. Everlab follows with real employer customers and a UK plan that has yet to start. Fountain Life and Biograph lead the luxury end. Q Bio has impressive technology and very little disclosed scale.

The field has one leader, one challenger that is gaining, and one strong specialist. Neko is ahead today, Function has the clearest route to catch it, and Prenuvo can still reshape the ranking if whole-body MRI earns stronger clinical backing.

Rank	Startup	Why it ranks here
1	Neko Health	Best overall mix of product quality, prepaid repeat demand, medical handoff and defensibility; first US clinic open since September 2026
2	Function Health	Largest reported membership (500,000+ since launch), strongest value and easiest national scaling model; retention remains the missing proof point
3	Prenuvo	Clear whole-body MRI leader with a 200,000+ scan biobank and the deepest research program, held back by price and unresolved screening evidence
4	Superpower	Cheapest broad lab membership with 64,000+ members (company-stated); no public renewal data yet
5	Everlab	Strongest emerging care platform, with employer customers and a large provider network; UK launch still undated
6	Fountain Life	Deep diagnostics and ongoing care across a premium-center network, but far too expensive for broad leadership
7	Biograph	Clinically rich assessment and specialist follow-up, constrained by two locations, premium pricing and limited public operating data
8	Q Bio	Ambitious multimodal exam and proprietary software, with commercial scale still concentrated in one flagship clinic and selected partners

If you want more recent data on this point, see the latest figures in our Longevity report ↓.